FDA Guidance on Diversity Plans in Clinical Trials: What You Need to Know | Bass, Berry & Sims PLC
The United States Food and Drug Administration (FDA) issued draft guidance on April 13, 2022, entitled, “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in […]